If you've started researching GLP-1 medications, you've likely encountered two very different price points: brand-name Wegovy at $1,300+ per month, or compounded semaglutide starting around $99 to $299 per month. The price gap is real — but so are the differences between these options.
Most telehealth providers won't give you a balanced explanation of both. Brand-name–only providers have no incentive to mention compounded options. Compounding platforms rarely explain the regulatory landscape honestly. This guide gives you what both sides leave out.
What "Brand-Name" Actually Means
Brand-name GLP-1 medications — Wegovy and Ozempic (semaglutide) by Novo Nordisk, and Mounjaro and Zepbound (tirzepatide) by Eli Lilly — are FDA-approved drugs. This means they've gone through extensive clinical trials involving tens of thousands of participants, with data reviewed by the FDA for safety, efficacy, and manufacturing quality.
Key characteristics of brand-name medications:
- Manufactured in FDA-inspected facilities with rigorous quality controls
- Exact dosing in pre-filled pens (no mixing or measuring required)
- Backed by large-scale clinical trial data (STEP trials for semaglutide, SURMOUNT trials for tirzepatide)
- Covered by some insurance plans, including the new Medicare GLP-1 Bridge program
- Subject to FDA post-market surveillance and adverse event reporting
The downside: cost. Without insurance, brand-name GLP-1 medications can exceed $1,000 per month. Even with insurance, copays often run $200–500 depending on your plan.
Sesame Care
Brand-name GLP-1 prescriptions — FDA-approved medications only
From $39/visit
Paid link · Compounded medications are not FDA-approved and are prepared by licensed pharmacies.
What "Compounded" Actually Means
Compounded GLP-1 medications contain the same active ingredient (semaglutide or tirzepatide) but are prepared by compounding pharmacies rather than the original manufacturers. Compounding has a long history in medicine — pharmacies have always custom-prepared medications when commercially available versions don't meet a patient's needs.
Compounded GLP-1s currently exist in a specific regulatory context: the FDA has allowed compounding of semaglutide and tirzepatide while evaluating whether to place them on the 503B exclusion list. This regulatory landscape is actively evolving in 2026.
503A vs. 503B: The Distinction That Matters
Not all compounding pharmacies are created equal. The two categories have meaningfully different oversight levels:
State-regulated pharmacies that compound medications based on individual prescriptions. They're inspected by state boards of pharmacy. Compounding happens on a per-patient basis. Think of this like a local pharmacy making a custom preparation for you specifically.
FDA-registered facilities that can produce compounded medications in larger batches without individual prescriptions. They're inspected by both the FDA and state boards. They follow current Good Manufacturing Practices (cGMP) similar to traditional pharmaceutical manufacturers. This is a higher standard of oversight.
When evaluating a compounding provider, asking whether they use a 503A or 503B pharmacy is one of the most important questions you can ask. 503B facilities offer a meaningfully higher level of regulatory oversight, including FDA inspection.
What Your Doctor Should Tell You (But Often Doesn't)
About Brand-Name Medications
- Manufacturer savings cards (NovoCare, LillyDirect) can dramatically reduce costs for commercially insured patients — sometimes to $0 copay
- Prior authorization can take days to weeks. Your doctor's office handles the paperwork, but you should follow up if you haven't heard back within a week
- Brand-name supply shortages have affected availability intermittently since 2023, though supply has stabilized significantly in 2026
About Compounded Medications
- Compounded medications are not FDA-approved — they haven't gone through the same clinical trial process. This doesn't mean they're dangerous, but it's a meaningful difference in the level of evidence
- Potency can vary between compounding pharmacies. Some third-party testing has found compounded preparations that don't match their labeled concentration
- The regulatory future is uncertain. The FDA has proposed adding certain GLP-1 drugs to the 503B exclusion list, which could affect compounded availability
- Vial-and-syringe format requires you to draw your own dose — slightly more complex than pre-filled pens
Questions to Ask Your Provider
Regardless of which direction you're leaning, these questions will reveal the quality of your provider's approach:
- "Is the medication you're prescribing brand-name or compounded? If compounded, which pharmacy prepares it?"
- "Is that pharmacy a 503A or 503B facility? Can I verify their accreditation?"
- "Do you offer both brand-name and compounded options, or only one?"
- "What third-party testing does the compounding pharmacy perform on their GLP-1 preparations?"
- "What happens to my treatment if compounded GLP-1s become unavailable due to FDA regulatory changes?"
- "How does your pricing compare to brand-name with manufacturer coupons?"
A provider who gets defensive or dismissive when you ask these questions is a provider you should reconsider. Good clinicians welcome informed patients.
Compare Your Options
Paid links · Compounded medications are not FDA-approved.
Making the Decision
There's no universally correct answer. The right choice depends on your insurance coverage, your budget, your comfort level with the regulatory landscape, and your provider's recommendation. Here are some general guidelines:
Brand-name may be the better choice if: Your insurance covers it with a manageable copay, you qualify for manufacturer savings programs, you prefer the simplicity of pre-filled pens, or you want the reassurance of full FDA approval and large-scale trial data.
Compounded may be the better choice if: You don't have insurance or your plan excludes GLP-1 coverage, cost is a primary barrier to treatment, you're comfortable with the vial-and-syringe format, and you've verified that your provider uses a reputable 503B pharmacy.
The most important thing is that you're making an informed decision — not one driven by marketing, fear, or incomplete information. Ask the questions, understand the trade-offs, and choose the path that makes sense for your specific clinical and financial situation.